Home › Compare › YEWTF vs ABBV
YEWTF yields 2631.58% · ABBV yields 3.06%● Live data
📍 YEWTF pulled ahead of the other in Year 1
Combined, YEWTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YEWTF + ABBV for your $10,000?
Environmental Waste International Inc., together with its subsidiaries, designs and develops environmental products for waste treatment and disposal in Canada and the United States. It researches, designs, develops, sells, and maintains systems based on the patented Reverse Polymerization process and related delivery system. The company provides systems for feed tire reduction, biological wastewater sterilization, shipboard food waste sterilization/dehydration, and batch-based infectious medical waste sterilization. Its tire system breaks the molecular bonds in tires and other rubber products and reduces them to their base components of carbon black, steel, and hydrocarbon vapors. The company also offers FS-6000 and FS-POD biocontainment and wastewater sterilization units; MD-1000, a three-stage, three chamber, medical waste reduction unit that produces a sterilized carbon residue; and AW-1000 to process and reduce animal waste into its constituents. Environmental Waste International Inc. was incorporated in 1987 and is headquartered in Whitby, Canada.
Full YEWTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.